Fujirebio Lumipulse G pTau217/B-Amyloid plasma ratio test recalled for inaccurate Alzheimer's disease results
What this means
Fujirebio's Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio test may produce inaccurate results that falsely suggest Alzheimer's disease or incorrectly flag patients for additional testing. The test can show higher-than-actual ratios, leading to wrong patient classifications compared to confirmed imaging or cerebrospinal fluid tests.
- If you work at a clinical or diagnostic lab, contact Fujirebio immediately about affected equipment (Model CL0073)
- Ask your healthcare provider or lab if your recent Alzheimer's disease screening used this test
- Discuss retesting with your doctor if you received unclear or positive results from this test
The agency's original wording
Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-1301-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering pet owners — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.